1,016 Eli Lilly and Company $LLY Shares Sold by DSG Capital Advisors LLC

DSG Capital Advisors LLC cut its stake in shares of Eli Lilly and Company (NYSE:LLY) by 3.0% in the third quarter, Holdings Channel.com reports. The institutional investor owned 32,491 shares of the company’s stock after selling 1,016 shares during the quarter. Eli Lilly and Company makes up about 5.4% of DSG Capital Advisors LLC’s holdings, making the stock its 3rd largest holding. DSG Capital Advisors LLC’s holdings in Eli Lilly and Company were worth $37,595,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Bank of America Corp DE bought a new stake in shares of Eli Lilly and Company in the second quarter worth $13,522,666,000. Jupiter Topco LLC bought a new position in shares of Eli Lilly and Company in the 2nd quarter worth approximately $4,667,180,000. Corient Private Wealth LP bought a new position in Eli Lilly and Company in the second quarter worth approximately $764,116,000. BlackRock Inc. lifted its position in Eli Lilly and Company by 1.6% during the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock valued at $81,009,981,000 after purchasing an additional 1,046,558 shares in the last quarter. Finally, State Street Corp increased its position in Eli Lilly and Company by 1.7% in the second quarter. State Street Corp now owns 36,215,754 shares of the company’s stock worth $43,438,262,000 after buying an additional 605,752 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Foundayo met the primary endpoint in a Phase 3 trial for obstructive sleep apnea, reducing breathing interruptions by up to an average of 44%. Lilly plans to seek FDA approval for the additional use by year-end, which could broaden the pill’s commercial opportunity beyond weight loss. Reuters article
• Positive Sentiment: Jefferies raised its price target to $1,700 and maintained a Buy rating, signaling continued analyst confidence in Lilly’s prospects. Jefferies price target
• Positive Sentiment: Lilly’s agreement with Hims & Hers and a similar arrangement with LifeMD expands digital access to its branded obesity medicines, including Zepbound and Foundayo. Hims’ share-price decline following its own disappointing results appears company-specific; coverage reported Lilly holding steady. Yahoo Finance article
• Negative Sentiment: The FDA is requiring GLP-1 drugmakers to add warnings about a possible increased risk of NAION, a rare eye condition that can cause sudden, potentially permanent vision loss. The class-wide warning could raise safety concerns for patients and investors, though the condition is rare. CNBC article

Insider Activity at Eli Lilly and Company

In related news, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the transaction, the executive vice president owned 4,137 shares in the company, valued at approximately $5,802,225.24. This represents a 54.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares of the company’s stock, valued at $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.14% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on LLY shares. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $1,413.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, October 20th. Truist Financial reaffirmed a “buy” rating and set a $1,612.00 price objective (up from $1,376.00) on shares of Eli Lilly and Company in a research report on Friday, October 30th. Guggenheim boosted their price objective on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a “buy” rating in a research note on Friday, September 18th. Royal Bank Of Canada increased their target price on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock an “outperform” rating in a report on Friday, October 30th. Finally, Citigroup raised their target price on shares of Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,416.64.

Eli Lilly and Company Stock Up 1.5%

LLY opened at $1,432.60 on Wednesday. The stock has a market cap of $1.35 trillion, a price-to-earnings ratio of 46.50, a price-to-earnings-growth ratio of 1.69 and a beta of 0.40. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. The firm’s fifty day moving average is $1,225.57 and its 200 day moving average is $1,104.56. Eli Lilly and Company has a fifty-two week low of $850.51 and a fifty-two week high of $1,453.00.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating analysts’ consensus estimates of $5.71 by $1.77. The business had revenue of $24.40 billion for the quarter, compared to analysts’ expectations of $22.58 billion. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The business’s quarterly revenue was up 38.6% on a year-over-year basis. During the same period last year, the firm earned $7.02 earnings per share. On average, sell-side analysts forecast that Eli Lilly and Company will post 35.70 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio is presently 22.46%.

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.